First national surveillance of susceptibility of extended-spectrum β-lactamase–producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel

• Published in: Diagnostic microbiology and infectious disease Vol. 57; no. 2; pp. 201 - 205
• Main Authors: Colodner, Raul, Samra, Zmira, Keller, Nathan, Sprecher, Hanna, Block, Colin, Peled, Nehama, Lazarovitch, Tzilia, Bardenstein, Rita, Schwartz-Harari, Orna, Carmeli, Yehuda
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.02.2007; Elsevier
• Subjects: Adult; Anti-Bacterial Agents - pharmacology; Bacteriology; beta-Lactamases - biosynthesis; Biological and medical sciences; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli - drug effects; Escherichia coli - enzymology; Escherichia coli Infections - epidemiology; Escherichia coli Infections - microbiology; Fundamental and applied biological sciences. Psychology; Hospitals, General; Humans; Infectious Disease; Infectious diseases; Internal Medicine; Israel; Israel - epidemiology; Klebsiella; Klebsiella - drug effects; Klebsiella - enzymology; Klebsiella Infections - epidemiology; Klebsiella Infections - microbiology; Medical sciences; Microbial Sensitivity Tests; Microbiology; Miscellaneous; Population Surveillance; β-Lactamase; Asia; Israel; Escherichia coli; β-Lactamase; Israel; Infection; Klebsiella; Sensitivity; Microbiology; Extended-spectrum β-lactamase; Bacteria; p-Lactamase; Antimicrobial agent; Enterobacteriaceae
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2006.07.011

Abstract In this 1st national surveillance study, the susceptibility pattern of 1011 consecutive isolates of extended-spectrum β-lactamase (ESBL)–producing Escherichia coli and Klebsiella spp. isolated from patients hospitalized in Israel hospitals, covering 62.3% of all general hospital beds in the country, was investigated. Proportion of susceptibilities (range among institutions, MIC50 /MIC90 in micrograms per milliliter) were to ertapenem 95.0% (88.8–100%, 0.19/0.75), imipenem 98.8% (88.8–100%, 0.25/0.38), meropenem 98.2% (90.0–100%, 0.06/0.19), piperacillin–tazobactam 59.1% (42.6–77.0%, 16/256), ciprofloxacin 17.2% (9.0–24.6%, 32/32), levofloxacin 17.8% (9.0–24.6%, 32/32), amikacin 74.5% (63.8–98.0%, 6/32), and gentamicin 19.3% (12.3–28.5%, 96/256). Coresistance, cross-resistance, and variability between institutions were high. Only carbapenems retain predicted activity against ESBL-producing E. coli and Klebsiella spp. across Israeli hospitals.